Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sucampo Pharma Europe

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

- PMLiVE

CDF chair regrets undermining NICE

But Prof Clark says he wholeheartedly supports the Institute

- PMLiVE

Janssen will cover cost of unsuccessful hepatitis C treatment

NHS England will only have to pay for Olysio if patient clears virus

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

- PMLiVE

Pharma condemns Cancer Drugs Fund cuts

NHS England says 16 medicines across 25 indications will be removed from list

- PMLiVE

NICE says cost of Dendreon’s cancer vaccine is too high

Another blow as the bankrupt company goes to auction next month

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

Lilly names head of corporate business development

Promotion for Darren Carroll

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links